Michael Wandell, based in Seattle, WA, US, is currently a President and CEO [mwandell@neothermaonocology.com] at NeoTherma Oncology - Inviting interest in Series A financing to conduct 'First-i, bringing experience from previous roles at Kahler Glen Community Assn, CRQ Insight LLC, Houston Area Translational Research Consortium (HATRC) and Epigenomics AG. Michael Wandell holds a 1979 - 1981 Clinical Pharmacology @ N.I.H. Fellowship in Medicine. With a robust skill set that includes Biotechnology, Lifesciences, Medical Devices, FDA, Technology Transfer and more, Michael Wandell contributes valuable insights to the industry. Michael Wandell has 2 emails on RocketReach.